Evidence map›Paper›PMID 41378050›Full record

ArticleTranslational cancer research2025

Expression and role of PD-L1 and SOX10 in hepatocellular carcinoma.

Byoung Chan So, Han Ju Park, Kyoung Min Kim, Ho Sung Park, Kyu Yun Jang, Myoung Ja Chung, Woo Sung Moon, Jae Do Yang, Ae Ri Ahn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Byoung Chan So *Department of Pathology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
Han Ju Park *Department of Pathology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
Kyoung Min KimDepartment of Pathology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
Ho Sung ParkDepartment of Pathology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
Kyu Yun JangDepartment of Pathology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
Myoung Ja ChungDepartment of Pathology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
Woo Sung MoonDepartment of Pathology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
Jae Do Yang *Department of Surgery, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.
Ae Ri Ahn *Department of Pathology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer and second leading cause of cancer-related mortality worldwide. This study aimed to investigate programmed death ligand-1 (PD-L1) and SRY-box transcription factor 10 (SOX10) expression in 191 HCC specimens and to analyze their association with clinicopathological features. Methods: Formalin-fixed, paraffin-embedded HCC specimens were assessed for PD-L1 and SOX10 expression using immunohistochemical staining. Clinicopathological features were obtained from medical records and by reviewing hematoxylin and eosin-stained slides. Results: The proportions of PD-L1-positive and SOX10-positive groups were 13.1% and 46.1%, respectively. PD-L1 positivity was significantly associated with higher T classification (P<0.001). SOX10 positivity was significantly associated with both higher T classification (P<0.001) and higher Edmondson-Steiner grade (P<0.001). In addition, PD-L1 expression showed a borderline correlation with SOX10 expression (P=0.054). In univariate analysis, both PD-L1 and SOX10 expression were associated with shorter overall survival (OS) and relapse-free survival (RFS) in patients with HCC. Conclusions: PD-L1 and SOX10 expression were associated with unfavorable prognostic factors as well as shorter OS and RFS. Further investigation is warranted to elucidate the molecular pathways through which SOX10 may regulate PD-L1 expression and to explore implications for immunotherapy response in patients with HCC.

Indexed as

Hepatocellular carcinoma (HCC)programmed death ligand-1 (PD-L1)SRY-box transcription factor 10 (SOX10)

Identifiers

PMID41378050
PMCPMC12686204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.